A Message From Our Program Leader
Over the last few decades, we have continued to push the envelope aiding in the development of cutting-edge interventional therapies for our patients. We aim to continue to support our patients with the latest innovations, shaping our clinical care.
About Our Program
The HonorHealth Research Institute is nationally recognized for its leadership and groundbreaking contributions in interventional and structural cardiology. Our program has played a pivotal role in advancing cardiovascular care through early adoption, clinical trial participation, and development of novel therapies and technologies that have transformed patient outcomes.
Our physicians and research teams have been instrumental in the development and testing of cutting-edge devices and procedures, including transcatheter valve therapies, renal denervation systems, advanced stent technologies, and minimally invasive solutions for coronary and valvular disease. This includes participation in pivotal trials that led to FDA approvals for devices such as the MitraClip, TriClip, and Tendyne Valve. HonorHealth was among the first institutions in the world to enroll patients in trials for novel approaches to shorten dual antiplatelet therapy (DAPT) following PCI. Our team also contributed to landmark studies in renal denervation for hypertension and lithotripsy for calcified coronary lesions, helping bring these therapies to clinical practice.
The program’s commitment to innovation extends to structural heart disease, where our specialists have led trials for transcatheter mitral and tricuspid valve repair and replacement, including the J-Valve and Tendyne systems. We continue to be a major contributor to IDE trials that shape the future of cardiovascular intervention.
Our team includes a multidisciplinary group of interventional cardiologists, structural heart specialists, advanced practice providers, and dedicated research coordinators. Together, we form one of the most active and accomplished cardiovascular research teams in the region, with a strong track record of “firsts” in Arizona and beyond.
Through collaboration, clinical excellence, and a relentless pursuit of innovation, HonorHealth Research Institute remains a driving force in the evolution of interventional and structural cardiology.
Interventional/Structural Cardiology Research Facts and Figures
In the last few years, the Interventional Cardiology program has enrolled more than 100 patients on clinical trials.
Pioneers in percutaneous intervention with drug eluting stents (DES) treating blockages in the vessels of the heart.
Interventional/Structural Cardiology Clinical Trials
We are currently involved in trials evaluating image-guided treatment of coronary lesions, pharmacologic and non-pharmacologic therapies during coronary interventions, new catheter-based interventions for valvular heart disease, and devices that support cardiac function in the setting of shock.